๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS ยท Real-Time Price ยท USD
1.810
+0.130 (7.74%)
At close: Nov 20, 2026, 4:00 PM EST
1.870
+0.060 (3.31%)
After-hours: Nov 20, 2026, 7:59 PM EST
โ† View all transcripts

Study update

Nov 19, 2026

Summary

In 33 efficacy-evaluable patients, MICVO showed a 39% confirmed ORR, 6.7-month median PFS and 81% 12-month OS probability; median OS was not reached. The dose cap reduced adverse events while maintaining efficacy, and a global phase III trial is planned for mid-2027.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Pyxis Oncology MICVO phase I Monotherapy Data Update. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you would need to press star one one on your telephone. You would then hear an automated message ad vising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Tom Civik, Chief Executive Officer. Please go ahead.

Tom Civik
CEO, Pyxis Oncology

Thanks, Michelle. Good morning, and thanks for joining us today for our clinical update on MICVO. My name is Tom Civik, and I'm the CEO here at Pyxis Oncology. I would like to start by sharing my deep thanks for the patients who put their trust in us, investigators who helped shape this program, a long list of partners who have supported and encouraged us, and for the Pyxis team who are working hard every day on this important journey to unlock the potential of MICVO. I'd also like to thank the organizers of the EORTC-NCI-AACR Symposium for hosting a wonderful conference this week in Barcelona, where a few hours ago, Dr. Faye Johnson of MD Anderson presented the updated data evaluating MICVO in second line and beyond head and neck squamous cell carcinoma.

Please note that today's presentation includes forward-looking statements, and we encourage you to review the related disclosures, which are available on our website. I'm very pleased to have Dr. Johnson join us today on the call. Dr. Johnson is a professor in the Department of Thoracic, Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. She specializes in head and neck cancers, with research focused on translating laboratory discoveries into new treatments. Dr. Johnson has led multiple clinical trials evaluating targeted therapies and immunotherapy combinations. During today's call, Dr. Johnson will present updated data from our phase I study of MICVO in second line and beyond head and neck cancer. She will also join us at the end to answer your questions.

I'm thrilled to report that based on the data you will see, MICVO continues to be uniquely positioned to become a meaningful treatment option for patients with cancer. On today's call, we'll start with the need, and it's significant. There is a large number of patients in the second line and beyond with head and neck cancers, and with the expected changes in the first line, there will be inadequate options for these patients. This evolving treatment paradigm has created a significant gap in effective options, and this is what drives us. I'll then pass it to Dr. Johnson, who will review the slides she presented a few hours ago at the conference, focusing on our program, MICVO, is a first-in-concept ADC with a novel ADC target in the tumor extracellular matrix.

The study, our team built and executed an innovative global study that allowed us to evaluate MICVO either after the current standard of care or after what seems likely to become the future standard of care. The study also evaluated key patient subgroups, including HPV status. The results show MICVO as monotherapy with a 5.4 mg per kg dose cap demonstrates substantial efficacy improvement with a safety profile that is consistent with other approved auristatin ADCs. With a little over two months since you last saw the data, we are thrilled to report that many key efficacy measurements have improved, and Dr. Johnson will share some very interesting new analysis on survival benefits. Finally, the data will show our clinical strategy to impact the safety profile of MICVO is working. Finally, I will review our path forward toward potential phase III initiation in mid-2027.

With that, let me start with the significant emerging need in second line and beyond head and neck cancer. Head and neck cancer is the seventh most common oncology tumor type, but despite this large patient population, there are relatively few therapies available in the recurrent metastatic setting. On the left side of the slide, you'll see head and neck cancer epidemiology estimates in 2030 in the U.S., broken out by line of therapy. 30,000 patients in the front line, 21,000 patients in the second line, and 8,000 patients progressing to the third line. With the emerging data from the EGFR bispecifics in combination with pembro , we think it's highly likely that the EGFR inhibitors will move to the front line. This is a promising time for patients with new front line options potentially becoming available soon.

However, this will create significant unmet need in the second line, as sequential retreatment with EGFR inhibitors in the first line and then second line is very unlikely. There is a need for a non-EGFR targeting mechanism in the second line and beyond, and with 21,000 patients in second line alone, there will be a significant population with very few and very poor options. On the right side of the slide, we summarize this opportunity for a differentiated mechanism of action to potentially improve care for a lot of these patients in second line. Let me put those current options in better context. Here are the limited options in second line head and neck that I was referring to. We're showing control arm data from KEYNOTE-040 and CheckMate 141 trials, which were large phase III studies in the second line setting.

These two studies used an investigator choice of cetuximab, docetaxel, and methotrexate. Unfortunately, with an ORR in the mid to high single digits, only a couple months of median progression-free survival, and roughly half a year of median overall survival, there is important work to be done to improve the care for these patients. With that, I'm really excited to pass it to Dr. Johnson to share the slides she just presented at the Triple Meeting and some additional analysis that have been added for this presentation. Dr. Johnson?

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Thank you very much. MICVO is a first-in-concept antibody drug conjugate that targets the extra B domain of fibronectin, or EDB-FN. This protein is expressed in the stroma of tumor cells, including head and neck squamous cell carcinoma, and with very low levels in normal adult human tissue. MICVO has site-specific conjugation, protease-cleavable linker, and an optimized auristatin payload with a drug-to-antibody ratio of four. It has a three-pronged mechanism of action, directly killing cancer cells, bystander killing, and eliciting an immune response. It is being tested here in recurrent metastatic head and neck squamous cell carcinoma, where we just heard about the unmet need.

This phase I study started as a dose escalation trial in multiple solid tumors and then progressed to a dose expansion at 5.4 mg per kg every three weeks in recurrent metastatic head and neck squamous cell carcinoma patients who had progressed on PD-1 immunotherapy and platinum, with or without prior EGFR therapy. The data I will present to you here are from the head and neck patients who received the 5.4 mg per kg dose in the cohort where we also instituted a dose cap, and that dose cap was instituted during the study for safety. This is a common strategy for antibody drug conjugates. There are 36 patients who are available for safety analysis and 33 available for efficacy analysis. The median study follow-up is 9.2 months, and the minimum follow-up is 7.4 months. The disease characteristics for the patients are shown here.

Notably, about two-thirds of these patients had a performance status of one. There was an equal number of HPV-positive and HPV-unrelated patients on the study. The median prior number of therapies was two, and most of these patients were being treated in the third line. By design, they all had prior platinum and anti-PD-1 immunotherapy. Then 69% had previously had a taxane, and the majority had also had anti-EGFR, including six patients who did receive the novel bispecifics petosemtamab and ficerafusp alfa. The confirmed overall response rate in this group of 33 patients is 39%. One patient, it is the prior slide. Yes. That was one patient with a complete response and 12 patients with partial response. In this population of patients, the disease control rate was 94%.

If you look at the waterfall plot on the left and the forest plots on the right, you can see that for the important subgroups, they all maintained a good response rate, and that includes patients by HPV status, line of therapy, prior taxane, prior EGFR, age, gender, and performance status. Importantly, the responses did not correlate with protein expression of EDB-FN that was measured in the tumors by immunohistochemistry. In the swimmer plot, we can see a good progression-free survival and an encouraging duration of response. That includes patients who are HPV-positive and HPV-negative, and that is the pink and blue range respectively. On the right side of this slide, in the 13 patients who responded, the median duration of response was 9.2 months, which is impressive in this group of pre-treated patients, especially given the historical data that Tom presented.

In the spider plot, we can see that responses were rapid. In fact, 69% of patients who responded did so by the first scan, and that first scan happened approximately six weeks after the first dose of drug. Responses were also deep, and 77% of responders achieved greater than 50% reduction in tumor size, and that is particularly important to our head and neck patients who suffer from tumor-related pain and difficulty in swallowing and speech. The median progression-free survival is shown in the next slide, and that is the pink line on the Kaplan-Meier curve. The median progression-free survival is 6.7 months. Looking at the table on the right side of the slide, that progression-free survival was maintained in all of the important subgroups, again, including HPV, prior anti-EGFR therapy, and prior taxanes, as well as line of therapy.

This was a single-arm study in which all patients received MICVO, so we do not have a comparator or control arm. As an exploratory analysis, we looked at progression-free survival for these same exact patients on the prior line of systemic therapy, and that is the blue line on the Kaplan-Meier curve, and that was 4.2 months. The overall survival data on the next slide are still maturing. Right now, the median survival has not been reached. The 12-month overall survival probability is 81%, and the lower bound of that 95% confidence interval is 62%. I cannot read my own slides, but it is well above 50%. On the right side of the slide, 11 patients have received subsequent therapy after MICVO, and looking at these agents, it is unlikely that those subsequent therapies are driving this very favorable survival data. Toxicity was as we would expect. That is on the next slide.

Toxicity is as we would expect from an agent, an antibody drug conjugate that has a microtubule targeting payload, the auristatin, also given to a patient population with advanced recurrent disease who are heavily pretreated. The treatment-related adverse events leading to discontinuation happened in about 14% of patients, and importantly, that occurred at a median of 162 days, which is about five months. That timing is important because, as you recall from a few slides back, most of these patients had an early benefit with reduction in tumor size by the first scan at six weeks. So, early efficacy and late significant toxicity. There were no treatment-related deaths or grade five toxicity. The most common treatment-related adverse events are shown on the right in the bar graphs. Again, pretty much as expected.

The notable toxicity that we have more data on in the next slide is the peripheral neuropathy. Peripheral neuropathy was common. As we expect, it did occur more frequently in patients who had had a prior taxane, and that is panel one. We had six patients on the study who had a grade three peripheral neuropathy. If you look at panel two, the median time to development of a grade three peripheral neuropathy was 5.5 months. So again, early efficacy, late toxicity. Of those six patients who had the grade three peripheral neuropathy, five have reduced to a grade one, and one is still suffering from a grade two. So, there is some degree of reversibility.

Looking at panels four and five, we see that the patients who had the peripheral neuropathy actually had more efficacy of drug, and that makes sense because it is very likely that patients who stayed on treatment longer were more likely to get this cumulative toxicity. In the next slide, we have an example of a patient who had significant peripheral neuropathy. This is a patient who had HPV-unrelated recurrent metastatic head and neck cancer, had prior treatment with cisplatin, cetuximab, docetaxel, nivolumab, and cetuximab, so heavily pretreated. The timeline on the right shows the grade of neuropathy and also the tumor size. You can see that this patient had an excellent response with the tumor size significantly decreased. The [inaudible] was held for almost three months because of the significant neuropathy, but the tumor response was maintained.

The tumor did not grow during that time. When the patient's neuropathy improved to grade one, he was retreated at a lower dose and had an additional response in the tumor. The drug had to be held again, but the neuropathy has reversed again to a grade one. I think that this is a single vignette, but consistent with my experience with patients I have treated on this trial, that they do maintain response when the drug is held and the neuropathy does improve. There is another patient example on the next slide, and this is a patient with an oral cavity cancer. You can see the CAT scan there with very large tumor in the oral tongue, and there is a picture that accompanies this. This is a patient who had a fantastic response to treatment.

The quantification of the tumor is shown in that middle panel on the top with the pink line, and the CAT scan and physical exam is shown in the bottom right. This patient had a confirmed partial response, over 70% reduction in the target lesion and a PFS of seven months. I think this is important for several reasons. First of all, this patient was not my patient, but very likely felt a whole heck of a lot better not having that painful lesion in his tongue. Also, if you look at the prior lines of treatment, really, there was no effective standard of care for this patient. I mentioned at the beginning that during the study, we had a dose cap, which is a common strategy for antibody drug conjugates, and this was done for safety.

This slide shows how the dose cap affected safety and efficacy in those patients. This is a little bit different dataset than I have been showing in the previous slides. These are all patients with high body weight who would be dose capped by the new approach. Nine of those patients had been treated prior to the dose cap and got a higher dose than the dose cap, and those are the patients in pink. Those patients in blue are the ones that were treated at the dose cap. If you look at the safety data on the right, you can clearly see decrease in treatment-related adverse events with the dose-capped patients. Looking at the left, the efficacy is maintained, looking at measures of efficacy such as overall response rate and disease control rate.

So one question is, in the next slide, if we can use expression of EDB-FN to guide which patients to treat, that is not the case. Looking at a H-score, immunohistochemistry for EDB-FN, and comparing that to response rates, there is no correlation. This analysis has been done with cutoffs with continuous variables. There is just no correlation between EDB-FN and response to treatment. This would not, in future studies, be a cutoff or biomarker for treating patients.

Tom Civik
CEO, Pyxis Oncology

All right. Thank you, Dr. Johnson. Appreciate you presenting that data, just not right now, but also at the meeting this week. Thank you so much. Let's move on to what we are going to do next. I am happy to report that we have already aligned with the regulatory authority advice on the design of this phase III study called Headliner. We plan to evaluate MICVO versus the current standard of care treatment in second line plus head and neck. We have designed Headliner in partnership with investigators around the world. It will be a global phase III trial in the second and third line setting. The study will enroll approximately 500 patients who have progressed following both a platinum-based therapy and an anti-PD-1 therapy and randomize them one-to-one to MICVO monotherapy or investigator choice of single-agent cetuximab, docetaxel, or methotrexate.

The co-primary endpoints of the study will be overall response rate and overall survival. The study is planned to begin in the middle part of next year, 2027. To provide some insight on the next slide into our expectations for Headliner, with the caveats we must always remember when making cross-trial comparisons, we are thrilled that MICVO's response rate, progression-free survival, and overall survival appear favorable compared to those single-agent chemotherapies or cetuximab observed in KEYNOTE-040 or CheckMate 141 studies. This gives us a lot of enthusiasm to start the Headliner study as soon as possible. I am excited to reiterate our plans to further advance MICVO in clinical development. What I hope you took away from today's discussion on the MICVO monotherapy data is that this novel mechanism of action fills an important treatment gap as the first-line landscape evolves and EGFR inhibitors move to the front line.

The rapid, deep, and durable responses are translating into clinically meaningful results and impressive survival benefits. The safety profile is well understood and manageable. Finally, we have a clear path forward toward a pivotal trial. For MICVO monotherapy, we have three important milestones highlighted on the bottom of the slide. Project Optimus feedback in the first quarter, updated overall survival in the first half of 2027, and first patient enrolled in the Headliner trial in mid-2027. While we did not talk about our combination study today, the program continues to advance. We expect to provide an update on our progress in December, followed by an update on initial durability and our recommended phase III dose in the second half of next year. Once again, thank you, Dr. Johnson. Thank you to all of you for joining us today.

We can now open the call for your questions or comments.

Operator

As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. The first question is going to come from Jeffrey La Rosa with Leerink Partners. Your line is open.

Jeff La Rosa
Analyst, Leerink Partners

Hi. Congrats on the update, and thanks for taking my question. Two for me. First, one thing that struck me in the data was the strength of MICVO's emerging durability data. Do you interpret that as evidence of its target or payload immunogenic mechanism, and has this data impacted your thoughts around MICVO's potential in the first-line setting? My second question is, could you talk a little bit more about Headliner's design and powering, and how your expectations might have evolved as you've, one, seen MICVO data, evolving, and then two, as we have at least one EGFR bispecific that's reached the market in the second line, and another likely that will soon be in the front line? Thanks.

Tom Civik
CEO, Pyxis Oncology

Sure. Well, thanks, Jeff. Yeah, really interesting questions. I think, first off, we were quite excited to be able to share the duration of response data that you saw today. I think 9.2 months median duration of response is impressive, and I think, as Dr. Johnson said, is encouraging for what this could mean for this program. I think, hopefully you saw in the swimmer plots that we have six patients that have a duration of response over six months, with five of them ongoing, and there's seven patients that have a duration of response less than six months. Three of those are ongoing. This data, I think, will continue to mature, but it gives us a lot of confidence that the original hypothesis around this program and its mechanism of action may be driving duration of response that's differentiated from what you would expect elsewhere.

I think short answer, Jeff, to the question is we're quite encouraged by the data we're seeing. We're going to obviously continue to watch it. It's an important variable to help maybe understand why early responses are leading to sustained and beneficial survival. Since I've got Dr. Johnson here, I'd love to ask her if she has any thoughts about what the early signs of durability might mean for this program.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah, I think that when we started enrolling patients on this trial, the things that we found very striking were the rapid responses and the deep responses, and the durability that we've seen. Even, we gave the vignette of the patient who had to hold therapy for several months and the tumor didn't grow. We've seen that multiple times. It's really striking, and I think as far as mechanism of action, it's both. It's this unique tumor-specific antigen, and then the auristatin, the potency of that drug to kill cancer cells.

Tom Civik
CEO, Pyxis Oncology

Yep. Jeff, hopefully that answers your question on durability and our excitement for the data we shared today. As it relates to Headliner, yeah, we're full steam ahead to fully stand up this trial, and hopefully our first patient dosed in the middle part of next year. Obviously, we're quite excited to get alignment with the FDA and the EMA at the end of 2025. The profile of the drug is emerging in front of you right now, so we're excited to continue those dialogues and partnership with the agencies about what is the best path forward for this program. My goal, get this drug to patients as quickly as possible. We're trying to design a trial that is attractive for the global investigator community, that answers the questions that we think need to be answered, to bring a new novel mechanism of action to the second line.

You asked me a direct question about stat plan. We're not going to disclose that yet today, but we expect that we will provide an update early next year. Did I get them all, Jeff?

Jeff La Rosa
Analyst, Leerink Partners

You did. Thanks a lot. Thanks.

Tom Civik
CEO, Pyxis Oncology

You bet.

Operator

Thank you. Our next question is going to come from Michael Schmidt with Guggenheim. Your line is now open.

Michael Schmidt
Analyst, Guggenheim

Oh, yeah. Hey, good morning. Thanks for taking my questions, and congrats on this great update today. I thought the lower neuropathy rates in the taxane-naive patients was very interesting. Obviously, makes sense, mechanistically speaking. Yeah, just curious. I think the patients in the study were, 70% of them were pre-treated with taxanes, and I'm just wondering if you had any sense of how that might look in phase III, and if that rate was lower, that could further drive tolerability benefits. Then I had a follow-up.

Tom Civik
CEO, Pyxis Oncology

Sure. Let me start, Michael, and thanks for the question. We had 11 patients in this study that did not receive a taxane. I am going to caveat, it is still a small n, but we only had one patient that did not receive a taxane that developed grade three peripheral neuropathy. It is enough to get us excited as to what it means for the future treatments in second-line head and neck cancer, as we see likely a chemo-free option in frontline, where patients are going to be much healthier when they would be getting MICVO in the second line. We are quite encouraged by that. It is small, but encouraging. Small data set, but encouraging. I think it also speaks to what you might expect in our frontline data set too, where you have less exposure to things like taxanes earlier on in the treatment.

I think the analysis is really important as we think about the development of the program. I suspect in the clinical trial, we will still have a lot of patients that have exposure to taxanes, and they are followed by platinum plus PD-1. The future state, when we are talking about all these drugs, including MICVO being approved, when patients are just getting this in their normal practice, not in a clinical practice, I think there is a lot of reasons to be excited about what some of these chemo-free or chemo-less options might mean for MICVO and its long-term profile. I would also like to get Dr. Johnson's point of view on that.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah. Yeah. I agree, and I will say our group, which is an academic group. We stopped giving taxane in the first line, because there are antibody drug conjugates that have microtubule targeting agents, and so we have mostly been giving carbo/5-FU/pembro first line. You make a very good point that we fully anticipate all three bispecifics will be approved as frontline therapy within the next year or two. We will have patients who have not been exposed to chemo, a significant number, and so that neuropathy from subsequent MICVO treatment should be lower. Of course, we have also learned about the neuropathy and developed mitigating protocols, and we are better at spotting it. I think that we will be better at treating patients and having lower rates from that mechanism as well.

Tom Civik
CEO, Pyxis Oncology

Yeah. Thanks, Dr. Johnson. Michael, it sounded like you had a part two of your question.

Michael Schmidt
Analyst, Guggenheim

Yeah, absolutely. This question just thinking about data we've seen in other tumor types, like in bladder cancer, with these tubulin-based ADCs, where it seems like a strong potential for synergistic activity with pembrolizumab. As I think about your pembro combo study, I am just curious, maybe for Dr. Johnson, if you think the tolerability profile here, especially with the dose cap now, is amenable to the combination. Just maybe when we think about some of the learnings from other tumor types to this type of ADC combination.

Tom Civik
CEO, Pyxis Oncology

Yeah. Michael, it is a really important question, and the good news is that we will be providing an update on our combination program of MICVO plus pembro in just a few weeks. We are excited to share that information. I think as we have shared publicly, we have prioritized frontline patients. We are dosing patients at both 3.6 and 4.4, regardless of HPV status, so it is quite a bit less drug. You may recall that when we disclosed our combo data at the end of last year, it showed a 71% response rate and a very clean safety profile. So we are quite excited to get an update to you on our combination data. I think you ask a very interesting question about not only what does the combination look like in head and neck, but where else might it be explored?

I think those are questions that, as a small biotech, we have resisted the urge to go too far, because we know that we have got this significant opportunity in front of us in second-line head and neck cancer in monotherapy, so we are putting the majority of our focus there. But when we start talking about life cycle options, the places to consider other development for MICVO, either as a monotherapy or in combination, the profile that we shared today, that Dr. Johnson presented at the Triple Meeting, give us a lot of confidence that we have unlocked a significant potential for this program in head and neck, but potentially beyond. So maybe Dr. Johnson, on combination, what are your thoughts there?

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah. I mean, the complicating factor here is that the frontline setting is very dynamic right now and probably going to be very different in a year or two. So from a strategy standpoint, that makes it challenging. I think if patients have chemo-free options like the EGFR bispecifics, they are going to want to try those first.

Tom Civik
CEO, Pyxis Oncology

Yeah.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah.

Tom Civik
CEO, Pyxis Oncology

Michael, did we get your question?

Michael Schmidt
Analyst, Guggenheim

Yes, you did. Thank you so much.

Tom Civik
CEO, Pyxis Oncology

All right. Thanks.

Operator

Thank you. The next question will come from Stephen Willey with Stifel. Your line is now open.

Stephen Willey
Analyst, Stifel

Yeah. Good morning. Thanks for taking the questions, and congrats on the update. Was just curious if you guys have a relative dose intensity statistic. I believe you're providing the proportion of patients who had a treatment-related adverse event that led to a discontinuation, and I think reductions as well. But I know you flagged a couple of patients who had to be paused on dose, and just kind of curious as to what the relative dose intensity might be here, and then I just have a follow-up.

Tom Civik
CEO, Pyxis Oncology

Yeah. Stephen, we have implemented, through the help of our investigators across the globe on this trial, a really thoughtful way of using dose modification to manage some of the AEs that were revealing themselves. And we see it as a really important feature of the program, that you can start off at 5.4, and the vast majority of patients can handle 5.4. But if they do have an AE that emerges, they can dose reduce to 4.4, 3.6, and you even saw a case that Dr. Johnson presented where a patient went down to 2.4 and still get benefit from being exposed to MICVO and reduce the toxicity that they were trying to manage. We have, through the help of our investigators, I think gotten a lot better at leveraging the opportunities to use dose modifications where necessary.

To answer your direct question, we have not disclosed dose intensity, but I think it is an interesting question that should be something that we consider producing down the road.

Stephen Willey
Analyst, Stifel

Okay. That's helpful. Maybe a question for Dr. Johnson. I guess when you look at the attrition rates of patients between frontline and second-line therapy, just in terms of those patients who do or do not receive subsequent therapy, I think a lot of the contemporary phase III's would suggest that rate is somewhere between 50% and 60%. I'm just curious if that's something that you see in your clinic, and whether or not you would expect that number to meaningfully improve in the context of some of these new regimens that are going to be moving into the frontline. Thanks.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah, good question. I do expect those numbers to improve for a couple of reasons. First, it depends on when you pulled those data. In the old days, when I started my career and dinosaurs roamed the Earth, most of our patients were smokers with HPV-negative disease, and they were current smokers, and they were falling apart. No one wanted to do trials in head and neck because the patients were so sick. Over time, we've gotten more and more HPV-positive patients who tend to be younger and much healthier, and they get to many lines of therapy. Even the smokers are generally not current smokers, they're former smokers, and they're healthier than our patients a couple of decades ago. That's one thing where I'm seeing more and more patients getting to subsequent lines of therapy.

I think the EGFR bispecifics are going to help us also because their toxicity profile with a chemo-free regimen is going to mean patients are less beat up with chemo. Their bone marrow's in better shape, that sort of thing. I do see more patients getting to subsequent lines of therapy. The other thing is, what subsequent line of therapy do you have? If you have someone who's kind of borderline of whether or not they can get more treatment and your option is methotrexate with a response rate of 6%, I'm going to tell that person to go to hospice. What is the chance of something good happening to that patient's very low?

But I think if you have someone who's progressing and you know you have a therapy that you can manage the toxicity and it's likely to be effective and shrink a tumor and make them feel better, you're much more likely to be aggressive and put them on the next line of therapy.

Tom Civik
CEO, Pyxis Oncology

What else, Steve?

Stephen Willey
Analyst, Stifel

Thanks for taking the questions.

Tom Civik
CEO, Pyxis Oncology

Great. Thanks, Stephen.

Operator

Our next question is going to come from Farzin Haque with Jefferies. Your line is open.

Farzin Haque
Analyst, Jefferies

Hi, everyone. Thank you for taking my question. One for the company maybe. Can you clarify for the six grade three PN cases, what was the median time from onset to improvement for the five that have completely resolved? Then for Dr. Johnson, when Genmab presents the full peto plus pembro data, which findings would most change your view of the size and composition of the second-line opportunity? Whether in Nectin-4 or MICVO, particularly efficacy and durability in the HPV status, tumor site, any patterns of progression, something along those lines?

Tom Civik
CEO, Pyxis Oncology

Yeah. Hey, Farzin. Thanks for the question. You're right, we had six patients that had grade three peripheral neuropathy in the data we disclosed back in September. That was an August data cut. We're now two months later. We have the exact same number of patients, six with grade three peripheral neuropathy. There's been no change in the incidence of grade three peripheral neuropathy. You may have noticed in Dr. Johnson's slide, we can now say that all six of those patients improved. Five of the six patients improved to grade one, and one improved to grade two. We haven't disclosed the time to resolution, but I think Dr. Johnson did share with you a patient story where it was different based upon the two times that that patient had grade three peripheral neuropathy reveal themselves.

Since we only have six patients, it's hard to do averages and means in that world. I would just say we were quite excited to see resolution for five of the six patients down to grade one or better, and one of the patient improving to grade two. I think time to resolution, we will continue to look at it and look forward to updating it down the road as the data becomes a bit more mature. Your second question was about what happens in the second line should peto get approved in the front line, I think. Is that right, Farzin?

Farzin Haque
Analyst, Jefferies

When you see the detailed data, what are you focused on basically that would inform your second-line ADC opportunity?

Tom Civik
CEO, Pyxis Oncology

I think what he's asking, Farzin's asking is, if we go to a future state where you use peto plus PD-1 in the front line, how do you choose what your second-line option?

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Second line, yeah. Yeah. I think we fully expect all three EGFR bispecifics to get approved for front line. There is a lot of discussion about what you do next, and it is essentially at this point a data-free zone. I think MICVO is well-positioned in that population. As we discussed earlier, those are patients who would not be taxane-exposed, so much lower chance of neuropathy. The data with the rapid deep responses is very compelling. I think MICVO is well-positioned to take the second line. If physicians decide to go back and give chemo again, carbo/5-FU, then we still saw efficacy in platinum-resistant patients and taxane-resistant patients and PD-1-resistant patients. It would still have a place as third line in that setting as well.

Tom Civik
CEO, Pyxis Oncology

Yeah, I mean, Farzin, I sort of think about it this way, that there are two patient populations, and it will be interesting to see how the data play out as it relates to HPV status in the frontline. If we just assume that two-thirds of the patients are HPV-unrelated or HPV-negative in the frontline, the treatment options for those patients are pretty limited, and MICVO's profile is emerging quite nicely in this phase I study. Hopefully it will maintain in our pivotal. As it relates to HPV-positive patients, I think we are still all awaiting what the data look like in that patient population in frontline. I would just say what we showed today, Farzin, looks quite attractive for the HPV-positive patient population, with a pretty significant response rate, over, or I should say exactly a nine-month median PFS.

The profile is shaping up quite nicely for MICVO in HPV-positive patients too.

Farzin Haque
Analyst, Jefferies

Great. Thank you for the color, and congratulations on the update.

Tom Civik
CEO, Pyxis Oncology

Thanks, Farzin.

Operator

Thank you. Our next question's going to come from Leonid Timashev with RBC. Your line is open.

Leonid Timashev
Analyst, RBC

Hey, guys. Thanks for taking my question. I had maybe one for Dr. Johnson, maybe more on the platinum side of things. I'm trying to understand, the Headliner trial requires platinum, but we're considering how the novel EGFR PD-1s may move up in therapy. I mean, would you fight for MICVO in second line if patients didn't strictly have platinum exposure? Would you end up using it in third line? Are there other ways that patients may have had platinum exposure if it's not in the metastatic setting? Just trying to understand maybe a bit more color around that platinum exposure requirement from Headliner. Thanks.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah. Actually, the majority of our recurrent metastatic patients have been exposed to platinum, because we are generally treating these patients with either concurrent chemoradiation with platinum, or if they get surgery, many of them get postoperative radiotherapy with concurrent cisplatin. A lot of those get exposed, and if they recur within six months of getting concurrent, they're considered platinum-resistant. That is one way that patients get platinum-exposed. I will say, though, that for the Headliner trial, the comparator arm is not a platinum-based therapy. I'm not sure what the plan is for patients who haven't gotten platinum.

Tom Civik
CEO, Pyxis Oncology

That's right.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah.

Tom Civik
CEO, Pyxis Oncology

Yeah, I mean, Leo, it's an interesting question because as the frontline setting changes, it hasn't changed yet. If you think about the future state of the world where EGFR bispecifics are in the frontline post-approval, the amount of time it would take for those patients to be enrolled in our trial is probably not until the second half of 2028. That's quite a bit of time between those patients meet their median PFS and have a washout period and then are ready to roll into our trial. So the current state for, let's just say, the first year of enrollment of Headliner, the standard of care is platinum plus PD-1, not only in the U.S. but globally.

Should some of the patients that are in clinical trials be looking for a second-line option and the timing works, obviously, we would welcome those EGFR patients into the trial, and we suspect that we will have a dataset that's large enough to answer the question that you're asking around EGFR bispecifics plus PD-1 that have seen that therapy in the frontline in our Headliner trial. There's no exclusion criteria for EGFR bispecifics, and we will welcome those patients into the study.

Operator

Thank you. The next question will come from [Charles Wallace] with H.C. Wainwright. Your line is open.

Speaker 9

Hi. Thanks for taking my question. This is Charles on for RK. First question from me, you mentioned that the EDB+FN levels didn't predict response to MICVO. I was just curious how you explain this lack of correlation to the target. That's my first question. Thank you.

Tom Civik
CEO, Pyxis Oncology

I'm going to go first. I'm going to go first, actually, Jessica. I think, Charles, it's such an interesting question because I think the entire thesis that we had behind MICVO when we first went from preclinical into the clinic was, let's go look for tumors that have a lot of EDB-FN, and that's a great place to start. When we started in our basket study, we were pleasantly surprised that we saw activity in multiple different tumors, but head and neck was one of those that we saw a really strong signal in, we decided to move into dose expansion and dose escalation with MICVO in head and neck for two different reasons: clinical efficacy and significant unmet need. We still believed that what we were going to see in the dataset was a correlation between high EDB-FN and efficacy.

When we've done this analysis, we were a little bit surprised, but then quite excited, because I think the thinking of the team now is that you maybe don't need a lot of EDB-FN, you just need some so that the monoclonal antibody has a place to land and be in the right environment for the antibody linker to be dropped and the payload then to be released. I think it opens up a lot of opportunities for us to think about other cancers, as long as there is EDB+FN present, which in our research has shown that EDB+FN is present in almost every solid tumor and very rarely found in normal tissue. Quite interesting science experiment, and we're actually quite pleased with where it ended. But Dr. Johnson, throw in if you'd like.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah. Well, we'd actually discussed this quite a bit before. I would say for many, most antibody drug conjugates, the antigen expression doesn't correlate with response. That's been a lot of debate and discussion in the oncology world. One exception to that seems to be the HER2 targeting agents, where there is a correlation. Although even in HER2 positive disease, the lower expressors do respond to ENHERTU, which is a potent, well-designed ADC. I think there's an analogy here, that as long as you have some threshold, so that the payload is released in the tumor stroma, you'll get direct tumor killing, bystander killing, and then an immune response. That's probably the mechanism underlying why we see responses regardless of EDB+FN expression.

Tom Civik
CEO, Pyxis Oncology

Sound good, Charles?

Speaker 9

Yeah, that's very helpful. Thanks for all the additional color. Maybe if I could sneak in one more question.

Tom Civik
CEO, Pyxis Oncology

You bet.

Speaker 9

I think it's, yeah, slide 21. When you're looking at patients that were dosed above the cap versus at the cap, the heavy body weight patients dosed at the cap actually had better clinical responses than those dosed at the cap. Just curious, what kind of underlying is this a discontinuation effect or Yeah.

Tom Civik
CEO, Pyxis Oncology

Yeah. Let's be careful with small numbers.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah.

Tom Civik
CEO, Pyxis Oncology

I think there were nine patients that received a dose above the cap and five that were capped that had weights that were over 80 kg for males and 70 kg for females. Charles, you didn't hear Dr. Johnson say it, and you won't hear me say it. I would say similar efficacy and much improved safety profile, which is what we've been saying for months, and now we're publicly disclosing the data that supports that. I think your hypothesis is potentially right, that this may be due to exposure, that you're seeing prolonged benefit, but we haven't cut the data that way. We're just showing disease control rate, response rate, and deep response, and then the safety profile.

We are quite confident that the dose cap has done exactly what we were hoping it would do by reducing the frequency and severity of the AEs of interest, but maintain efficacy, and consistent with almost every other ADC in the market today.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah, and I'll just add, I agree with that. Based on there's nine patients in one subgroup and five in the other, there's a reason that there's not statistical analysis of these data. There's just not enough replicates to do it. And I don't see the efficacy data as being different between the two groups, given those limitations.

Tom Civik
CEO, Pyxis Oncology

Sorry, Charles. Similar efficacy, much improved safety profile.

Speaker 9

Okay. Very clear. Thank you.

Tom Civik
CEO, Pyxis Oncology

You bet.

Operator

Our next question is going to come from Derek Archila with Wells Fargo. Your line's open.

Derek Archila
Analyst, Wells Fargo

Hey, good morning, and thanks for taking a question, and congrats on the data. Maybe a couple from us. Just, maybe I missed this, but just in terms of the 12-month OS that you're showing, and relative to kind of what standard of care in physician's choice would be in Headliner, I guess, how do you think about the margin there for success? So maybe that's question one.

Tom Civik
CEO, Pyxis Oncology

Well, Derek Archila, I think there's a lot of white space. What we've seen in CheckMate and KEYNOTE, which used the exact same control arm that we have for Headliner, had somewhere between five, and you could argue up to seven months. I think there's a lot of white space. 81% 12-month OS probability, it's still early. I'm not going to say anything different than that. It's still early, but it's very encouraging. And the fact that we did this additional analysis to look at subsequent therapies to give us even more confidence that there's not something else that's potentially driving the OS benefit, I think there's a lot of white space. And I think we remain convinced that the two primary endpoints in Headliner, response rate and overall survival, are well within our grasp to de-risk the program as we move into phase III.

I don't know, Dr. Johnson, how do you feel about the OS data?

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

Yeah, I mean, it's very promising, and it's strikingly better than our standard of care. The bar is low for the standard of care, for drugs like single-agent cetuximab, methotrexate, single-agent docetaxel, hence the unmet need.

Tom Civik
CEO, Pyxis Oncology

Yeah.

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

So.

Derek Archila
Analyst, Wells Fargo

Got it. Very helpful. Just to follow up on first-line questions. Essentially, we've proved out, I think, to some degree around the PN and looking at these earlier line patients with kind of lower risk there. I guess, you guys have been talking about second line as kind of the white space and the opportunity, but with kind of the update coming later this year, in December for MICVO/pembro in the first-line kind of setting, I guess, how are you starting to frame that up in terms of an opportunity, and ultimately, will you get more convicted post-December data? Thanks.

Tom Civik
CEO, Pyxis Oncology

Yeah, I think Dr. Johnson alluded to it, and I'm going to reiterate it, Derek. We see a really significant opportunity to help a lot of patients in second line head and neck with the profile that's emerging from MICVO. In 20,000 patients with very limited treatment options, we think that opportunity is underappreciated by many, and we're quite excited to continue to advance the program in second line. We will be updating everyone on our combo data in just a few weeks. As we've disclosed, we have enrolled more than 20 patients in front line at the dose of 3.6 and 4.4. The front line setting has emerged with the EGFR bispecific, setting a really high bar that's super exciting for patients and allows us to know what we would have to beat to be competitive in front line head and neck cancer.

I hope you've heard me say this many times, Derek, which is the data that we'll share this next month will be response rate and safety. It will need more time to truly evaluate the durability of the program, and I think it will also be informative for how the combination of MICVO plus pembro performs, and whether or not head and neck is the only place that we would consider pursuing that combination. So, we're excited, really quite excited to be able to update you on our head and neck strategy in a very short period of time, and I think the data should inform multiple different places that could be exciting about the combination.

Derek Archila
Analyst, Wells Fargo

Excellent. Thanks, Tom.

Tom Civik
CEO, Pyxis Oncology

You bet.

Operator

Our next question is going to come from Gaurav Maini with LifeSci Capital. Your line is open.

Gaurav Maini
Analyst, LifeSci Capital

Hey, good morning. This is Gaurav on for Sam. Just one from us. Could the team comment on any notable differences on how dose adjustments and/or reductions will be handled as we think about the phase III versus the prior trial? If so, how should we be thinking about the potential impacts on efficacy and safety outcomes relatively?

Tom Civik
CEO, Pyxis Oncology

Yeah. We have, with our investigators, built a really thoughtful way to leverage dose reductions and modifications for this patient group. I will maybe just start with, early on in our dose escalation study, we found that we had an active dose between 3.6 and 5.4. That gives us a lot of confidence that if we do dose reduce or dose delay, that you are still in an active dose that could help the patient continue to derive benefit for a long period of time. I would expect that as we think, I am not even going to expect. I know what we will do for the pivotal trial is leverage the work that we did by using dose modifications specifically for peripheral neuropathy, and implement that as part of our protocol.

It's done exactly what we were hoping it would do. I think executing it with very clear direction for the phase III trial will be part of our goal. Dr. Johnson, I know you've been a strong advocate for this. Is there maybe anything that you would add?

Faye Johnson
Professor of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

No, we've learned a lot. We've learned a lot about how to manage the peripheral neuropathy, how to prevent it. Thank goodness the patients maintain their response when they take treatment breaks. That's a huge benefit, and it really allows us to dose reduce confidently and give those treatment breaks. I will say one thing biologically, and this is my opinion, since we don't have data to address this, but my thought is that if you reduce the size of the tumor, you will need less drug because you'll need less antibody because there'll be less EDB-FN for it to bind to. So that may be the mechanism behind why we're maintaining those responses with the lower doses. But I know we don't have data. It just makes sense from a cancer biology standpoint.

Tom Civik
CEO, Pyxis Oncology

You got it. Thank you. Is there another question?

Operator

Our next question is going to come from Andy Hsieh with William Blair. Your line is open.

Andy Hsieh
Analyst, William Blair

Great. Thanks for taking my question. Quick one, just curious about the efficacy update. Was that primarily driven by one confirmed partial response? If you can comment on some of the unconfirmed partial responses, how likely are they to get confirmed later down the road?

Tom Civik
CEO, Pyxis Oncology

Sure. Yep.

Andy Hsieh
Analyst, William Blair

I have a follow-up.

Tom Civik
CEO, Pyxis Oncology

Okay. I think we updated three different efficacy measures, response rate, PFS, and overall survival. Let me just work backwards. Overall survival went to 81% 12-month OS probability. Median PFS went to 6.7 months. Our confirmed overall response rate moved to 39%. You asked a specific question about what drove that. There was a patient in the last data cut that was stable disease that converted to an unconfirmed PR very, very quickly after the data cut, and then confirmed to a confirmed responder. That is the update to this data. Did I answer your question, Andy, about where the patient.

Andy Hsieh
Analyst, William Blair

Yeah. Going forward, unconfirmed conversion?

Tom Civik
CEO, Pyxis Oncology

Oh, yeah. I am sorry. That is right. You had asked about that. There were four unconfirmed patients that will not confirm. Two of them had PD, one was lost to follow-up, and the third one was on drug for over 200 days. We were unable to get a confirmatory scan before they did eventually PD well over 200 days after being on therapy. So, those four patients will not confirm. There are obviously some patients with stable disease that you probably have seen in our waterfall. Those patients, as we have already seen with other patients, still have the opportunity to confirm as well. So, in two short months, I am quite pleased to be sitting here saying that the efficacy has improved in multiple different areas, and that safety was maintained despite two more months of therapy.

The resolution of the grade three peripheral neuropathy gives me a lot of excitement on what the future holds for MICVO in the pivotal trial.

Andy Hsieh
Analyst, William Blair

Got it. That is super helpful. There seems to be a positive correlation between the response and peripheral neuropathy, just like you said. I am interested to hear from you, do you plan to release the 3.6 mg data just from the Project Optimus perspective? It will be kind of interesting to see if there is this efficacy and safety exchange at a lower dose.

Tom Civik
CEO, Pyxis Oncology

Sure. We haven't publicly said whether or not we will disclose the 3.6 data in a future time. I think hopefully we've shown that we like to be driven scientifically, and where there's a scientific question to be answered, we are quite interested in sharing it, which is why we're here in Barcelona today. The excitement that we have for 5.4 with the dose cap, Andy, is where we're putting our effort because we think it is the dose that has the best benefit-to-risk ratio. We have a lot of confidence in our discussions that are coming up with the agency around Project Optimus to be able to move forward with 5.4 with the dose cap. Our excitement remains high.

Andy Hsieh
Analyst, William Blair

Got it. Helpful. Thank you.

Tom Civik
CEO, Pyxis Oncology

You bet. Thanks for the question.

Operator

There is no further questions in the queue at this time. I will turn it back over to Tom for closing remarks.

Tom Civik
CEO, Pyxis Oncology

All right, Michelle. Thanks for taking care of us. Thank you all for the questions, and thanks for joining us today. We are looking forward to continuing to advance this important potential therapy and to continue to update you all on our progress. Thank you very much, and take care.

Operator

This concludes today's conference call. Thank you for participating, and you may now disconnect.